COVID-19 Vaccine Related Codes

Related Pages
On This Page

COVID-19 Vaccine Codes

Preview Posting of COVID-19 Vaccine Codes and Crosswalk in Anticipation of Potential Vaccine Availability under Emergency Use Authorization (EUA)

Note: Codes will become effective only upon EUA issuance of COVID-19 vaccine(s) by the Food and Drug Administration (FDA)

The codes and crosswalk for candidate COVID-19 vaccines will be posted for preview in phases as the late-stage clinical trials for candidate vaccines progress. Additional vaccines will be added to this list as they enter late-stage clinical trials.

The following downloadable table provides a preview of the vaccine codes that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines currently being studied in clinical trials.

To support this effort, the CDC is working closely with data partners responsible for the creation and distribution of vaccine codes and drug compendia publishers to coordinate the release of codes in advance of potential EUAs to enable systems and users that require these codes to prepare in advance.

The codes for these vaccines are also included in the vaccine code set files.

American Medical Association (AMA) COVID-19 CPT® vaccine product and administration codes are now available on the AMA web site.  The CPT vaccine product codes are included in the Preview COVID-19 table and the CDC vaccine code sets.  You can access further information regarding the COVID-19 CPT codes, as well as the associated coding guidance, using the following link:

https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codesexternal icon

Download the Preview Table for US vaccine administration only: PDF Versionpdf icon | Excel Versionexcel icon

Preview Posting of COVID-19 Vaccine Codes and Crosswalk. Provided in anticipation of potential vaccine availability under Emergency Use Authorization (EUA) Data as of 7/15/2021. Codes will become effective for US vaccine administrations only upon EUA issuance of COVID-19 vaccine(s) by the Food and Drug Administration (FDA). All CVX codes are associated to the new Vaccine Group “COVID-19”
CVX Code CVX Long Description CVX Short Description Sale Proprietary Name Sale Labeler MVX Code Unit of Sale NDC10 (UOS) UoS Package Unit of Use NDC10 (UOU) Presentation CPT Code CPT Description
207 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose COVID-19, mRNA, LNP-S, PF, 100 mcg/ 0.5 mL dose Moderna COVID-19 Vaccine Moderna US, Inc. MOD 80777-273-99 CARTON, 10 MULTI-DOSE VIAL 5mL EACH 80777-273-10 VIAL, 5 mL, MULTI-DOSE VIAL 91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use
207 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose COVID-19, mRNA, LNP-S, PF, 100 mcg/ 0.5 mL dose Moderna COVID-19 Vaccine Moderna US, Inc. MOD 80777-273-98 CARTON, 10 MULTI-DOSE VIAL 7 mL EACH 80777-273-15 VIAL, 7 mL, MULTI-DOSE VIAL 91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use
208 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose Pfizer COVID-19 Vaccine Pfizer-BioNTech PFR 59267-1000-2 CARTON, 195 MULTI-DOSE VIALS 59267-1000-1 MULTI-DOSE VIAL 91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use
208 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose Pfizer COVID-19 Vaccine Pfizer-BioNTech PFR 59267-1000-3 CARTON, 25 MULTI-DOSE VIALS 59267-1000-1 MULTI-DOSE VIAL 91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use
210 SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL AstraZeneca COVID-19 Vaccine AstraZeneca Pharmaceuticals LP ASZ 0310-1222-15 CARTON, 10 MULTI-DOSE VIALS 0310-1222-10 MULTI-DOSE VIAL, 10 DOSES 91302 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5×1010 viral particles/0.5mL dosage, for intramuscular use
212 SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL Janssen COVID-19 Vaccine Janssen Products, LP JSN 59676-580-15 CARTON, 10 MULTI-DOSE VIALS 59676-580-05 VIAL, MULTI-DOSE 91303 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5×1010 viral particles/0.5mL dosage, for intramuscular use
211 SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose COVID-19 vaccine, Subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL Novavax COVID-19 Vaccine Novavax, Inc. NVX 80631-100-10 CARTON, 10 VIAL, MULTI-DOSE 80631-100-01 VIAL, MULTI-DOSE, 5 mL 91304 Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use
Unspecified US COVID-19 Vaccine CVX Code
CVX Code CVX Long Description CVX Short Description Vaccine Status
213 SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED Inactive Unspecified code for COVID-19 not to be used to record patient US administration. May be used to record historic US administration if product is not known. CVX code 500 should be used to record Non-US vaccine where product is not known.

Download the Preview Table for Non-US vaccine administration only: PDF Versionpdf icon | Excel Versionexcel icon

Preview Posting of COVID-19 Vaccine Codes and Crosswalks to be used for Non-US vaccine administration. All COVID-19 related CVX codes are associated to the Vaccine Group “COVID-19”. Data as of 07/15/2021. CVX and MVX codes are identified for vaccines that have received emergency authorization from the World Health Organization (WHO), US Food and Drug Administration (FDA) or both. CVX codes have also been added without associated MVX for vaccines that are manufactured and administered outside the US but which have not been authorized by the WHO. The list of vaccines not authorized by the WHO may be incomplete. The list of vaccines indicated to be WHO-authorized will be updated periodically as the CDC monitors WHO published information.
CVX Code CVX Long Description CVX Short Description CVX Note CVX Status MVX Code MVX Manufacturer Product Tradename(s)
207 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose EUA 12/18/2020, 2-dose vaccine. Used to record Moderna vaccines administered in the US and in non-US locations (includes tradename Spikevax) Active MOD Moderna US, Inc. Moderna COVID-19 Vaccine (non-US Spikevax)
208 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose EUA 12/11/2020, 2-dose vaccine. Used to record Pfizer vaccines administered in the US and in non-US locations (includes tradename Comirnaty) Active PFR Pfizer, Inc Pfizer-BioNTech COVID-19 Vaccine (Non-US COMIRNATY)
210 SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL Potential EUA, 2-dose vaccine. AstraZeneca vaccine is authorized by the WHO and recognized towards immunity in the US. Non-US WHO authorized tradenames/identifiers include VAXZEVRIA, AZD1222, ChAdOx1 nCoV-19, COVISHIELD Active ASZ AstraZeneca AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD)
212 SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL EUA 02/27/2021, 1-dose vaccine. Used to record Janssen/J&J vaccines administered in the US and in non-US locations Active JSN Janssen Janssen (J&J) COVID-19 Vaccine
510 SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm) COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) WHO authorized pandemic vaccine. Recognized towards immunity in US Non-US SPH Sinopharm-Biotech Sinopharm (BIBP) COVID-19 Vaccine
511 SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac) COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) WHO authorized pandemic vaccine. Recognized towards immunity in US Non-US SNV Sinovac Coronavac (Sinovac) COVID-19 Vaccine
500 SARS-COV-2 COVID-19 Non-US Vaccine, Specific Product Unknown COVID-19 Non-US Vaccine, Product Unknown Pandemic Non-US Covid Administration – specific CVX or product unknown Non-US
501 SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (QAZCOVID-IN) COVID-19 IV Non-US Vaccine (QAZCOVID-IN) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
502 SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN) COVID-19 IV Non-US Vaccine (COVAXIN) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
503 SARS-COV-2 COVID-19 Live Attenuated Virus Non-US Vaccine Product (COVIVAC) COVID-19 LAV Non-US Vaccine (COVIVAC) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
504 SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light) COVID-19 VVnr Non-US Vaccine (Sputnik Light) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
505 SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik V) COVID-19 VVnr Non-US Vaccine (Sputnik V) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
506 SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CanSino Biological Inc./Beijing Institute of Biotechnology COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
507 SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences) COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
508 SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention) COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
509 SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (EpiVacCorona) COVID-19 PS Non-US Vaccine (EpiVacCorona) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US

COVID-19 Emergency Use Authorization Recipient and Caregiver Fact Sheets

Preview Posting of Codes for Emergency Use Authorization (EUA) Fact Sheets for Recipients and Caregivers

Vaccine information statements (VISs), used only for licensed vaccines, will not be available for COVID-19 vaccines while they are under Emergency Use Authorization (EUA). For vaccines under an EUA, the FDA requires a vaccine-specific Fact Sheet for Recipients and Caregivers be provided to vaccine recipients or their caregivers.

The COVID-19 vaccine-related codes are provided in anticipation of potential vaccine availability under an EUA. If a vaccine is not authorized, the code will be retired.

The FDA issued Emergency Use Authorization for the Moderna COVID-19 vaccine on Friday December 18, 2020.  Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccineexternal icon

The FDA issued Emergency Use Authorization for the Pfizer BioNTech COVID-19 vaccine on Friday December 11, 2020.  Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccineexternal icon

The FDA issued Emergency Use Authorization for the Janssen (Johnson & Johnson) COVID-19 vaccine on Saturday February 27, 2021.  Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccineexternal icon

The following downloadable VIS code files will include the new EUA Fact Sheet for Recipients records:

Preview Posting of Codes for Emergency Use Authorization (EUA) Fact Sheets for Recipients and Caregivers”
CVX Code EUA Recipient/Caregiver Fact Sheet Description Document Barcode String Edition Date Edition Status HTML URL PDF URL VIS GDTI document code
207 COVID-19 Moderna Vaccine EUA Recipient-Caregiver Fact Sheet 253088698300034911201201 12/01/2020 Historic https://www.cdc.gov/vaccines/covid-19/eua/modernatx.html https://www.cdc.gov/vaccines/covid-19/eua/modernatx.pdfpdf icon 0886983000349
207 COVID-19 Moderna Vaccine EUA Recipient-Caregiver Fact Sheet 253088698300034911210401 6/24/2021 Current https://www.cdc.gov/vaccines/covid-19/eua/modernatx.html https://www.cdc.gov/vaccines/covid-19/eua/modernatx.pdfpdf icon 0886983000349
208 COVID-19 Pfizer BioNTech Vaccine EUA Recipient-Caregiver Fact Sheet 253088698300033211210501 6/25/2021 Current https://www.cdc.gov/vaccines/covid-19/eua/pfizer.html https://www.cdc.gov/vaccines/covid-19/eua/pfizer.pdfpdf icon 0886983000332
210 COVID-19 AstraZeneca Vaccine EUA Recipient-Caregiver Fact Sheet 253088698300035611210201 02/01/2021 Current https://www.cdc.gov/vaccines/covid-19/eua/astrazeneca.html https://www.cdc.gov/vaccines/covid-19/eua/astrazeneca.pdfpdf icon 0886983000356
212 COVID-19 Janssen Vaccine EUA Recipient-Caregiver Fact Sheet 253088698300036311210201 7/8/2021 Current https://www.cdc.gov/vaccines/covid-19/eua/janssen.html https://www.cdc.gov/vaccines/covid-19/eua/janssen.pdfpdf icon 0886983000363

*Edition date is the date of the barcode generated-edition date and does not reflect the exact date that the EUA Fact Sheet was issued.

Top of Page
Page last reviewed: May 11, 2021
Content source: National Center for Immunization and Respiratory Diseases